New Graves' drug enters first human safety trial

NCT ID NCT07305818

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 24 times

Summary

This early-stage study tests a new drug called MER511 in 100 adults with Graves' disease. The main goal is to see if the drug is safe and what side effects it may cause. Participants will receive the drug either through a vein or under the skin, and blood tests will check how the body processes it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Site # 1101

    RECRUITING

    Hollywood, Florida, 33024, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1102

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1103

    RECRUITING

    Phoenix, Arizona, 85053, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1104

    RECRUITING

    Columbus, Ohio, 43203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1105

    RECRUITING

    Webster, Texas, 77598, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1107

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Site # 1108

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.